Patents Examined by Iqbal H Chowdhury
  • Patent number: 11884923
    Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of preparing tagatose using the same.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: January 30, 2024
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Young Mi Lee, Eul-Soo Park, Il Hyang Park, Sun Mi Shin, Sung Jae Yang, Ran Young Yoon, Eun Jung Choi, Seong Bo Kim, Seung Won Park
  • Patent number: 11866737
    Abstract: The invention relates to a 2-isopropyl malate synthase, a genetically engineered bacterium for producing L-leucine and application thereof and belongs to the field of metabolic engineering. The genetically engineered bacterium is obtained by overexpressing an isopropyl malate synthase coding gene leuAM for relieving feedback inhibition by L-leucine, an acetohydroxy acid synthase coding gene ilvBNM for relieving feedback inhibition by L-isoleucine, a 3-isopropyl malate dehydrogenase coding gene leuB and a 3-isopropyl malate dehydratase coding gene leuCD in host cells. The genetically engineered bacterium for producing the L-leucine is free from nutritional deficiency, rapid in growth, short in fermentation period, high in yield and high in conversion rate.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: January 9, 2024
    Assignee: Tianjin University of Science and Technology
    Inventors: Chenglin Zhang, Qingyang Xu, Yanjun Li, Yu Zhang, Yingzi Li, Fuzhou Zhu, Nan Lu, Shibao Han, Xierong Dong, Zishen Wang, Hao Xu, Ziyi Li
  • Patent number: 11851662
    Abstract: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.
    Type: Grant
    Filed: June 2, 2018
    Date of Patent: December 26, 2023
    Assignee: Ambrx, Inc.
    Inventors: Sigeng Chen, Yingchun Lu, Feng Tian
  • Patent number: 11851691
    Abstract: The present disclosure provides a fusion protein comprising a fucosidase or a truncated fragment or a mutant thereof fuses with either N-terminal end or C-terminal end of the endoglycosidase or a truncated fragment of mutant thereof. The present disclosure also provides a nucleic acid molecule expressing the fusion protein and a method for remodeling a glycan of an antibody Fc region.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: December 26, 2023
    Assignee: CHO PHARMA INC.
    Inventors: Kuo-Ching Chu, Lin-Ya Huang, Yi-Fang Zeng
  • Patent number: 11845923
    Abstract: Provided herein are modified Archaeal family B polymerases derived from the Archaeal microorganism Pyrococcus abyssi that exhibit improved incorporation of nucleotide analogues utilized in DNA sequencing.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: December 19, 2023
    Assignee: Singular Genomics Systems, Inc.
    Inventors: Souad Naji, Carl W. Fuller, Eli Glezer, Andrew Spaventa
  • Patent number: 11834692
    Abstract: Disclosed are components and methods for preparing tagatose from galactose via isomerization reactions using engineered components. The engineered components include microbial cells and methods for preparing microbial cells that have been engineered to catalyze isomerization of galactose to tagatose, in which the microbial cells express cytoplasmically an exogenous L-arabinose isomerase enzyme. The disclosed microbial cells may further be modified for use in methods for preparing tagatose from galactose via isomerization reactions where the microbial cells are treated with reagents that permeabilize the cells. The disclosed methods enable isomerization reactions of galactose to tagatose at relatively high rates, high conversions, and elevated temperatures.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: December 5, 2023
    Assignee: Trustees of Tufts College
    Inventors: Nikhil U. Nair, Josef R. Bober
  • Patent number: 11834690
    Abstract: The invention provides a non-naturally occurring microbial organism having a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The invention additionally provides a method for producing 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid. The method can include culturing a 6-aminocaproic acid, caprolactam or hexametheylenediamine producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: December 5, 2023
    Assignee: Genomatica, Inc.
    Inventors: Mark J. Burk, Anthony P. Burgard, Robin E. Osterhout, Priti Pharkya
  • Patent number: 11827900
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Patent number: 11827692
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: November 28, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Patent number: 11802300
    Abstract: A genetically engineered strain having high-yield of L-valine is disclosed. Starting from Escherichia coli W3110, an acetolactate synthase gene alsS of Bacillus subtilis is inserted into a genome thereof and overexpressed; a ppGpp 3?-pyrophosphate hydrolase mutant R290E/K292D gene spoTM of Escherichia coli is inserted into the genome and overexpressed; a lactate dehydrogenase gene ldhA, a pyruvate formate lyase I gene pflB, and genes frdA, frdB, frdC, frdD of four subunits of fumaric acid reductase are deleted from the genome; a leucine dehydrogenase gene bcd of Bacillus subtilis replaces a branched chain amino acid transaminase gene ilvE of Escherichia coli; and an acetohydroxy acid isomeroreductase mutant L67E/R68F/K75E gene ilvCM replaces the native acetohydroxy acid isomeroreductase gene ilvC of Escherichia coli. Furthermore, the L-valine fermentation method is improved by using a two-stage dissolved oxygen control. The L-valine titer and the sugar-acid conversion rate are increased.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: October 31, 2023
    Assignee: TIANJIN UNIVERSITY OF SCIENCE & TECHNOLOGY
    Inventors: Xixian Xie, Heyun Wu, Jiachu Wang, Faqing Wu, Xiaoqian Liu, Yanan Hao
  • Patent number: 11788103
    Abstract: The disclosure relates to the combination of a primary fermentation that converts gas to acetate with a secondary fermentation that converts acetate to a target product. Preferably, the gas contains carbon dioxide, such that the disclosure enables the fixation of carbon dioxide into useful products. The fermentations may be any combination of aerobic and anaerobic, batch and continuous. The fermenting microorganisms may typically be bacterial or fungal.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: October 17, 2023
    Assignee: LanzaTech, Inc.
    Inventors: Sean Dennis Simpson, Allan Haiming Gao, Robert John Conrado, James Daniel Winkler, Alexander Paul Mueller, Steven Brown, Loan Phuong Tran, Michael Koepke, Christophe Daniel Mihalcea
  • Patent number: 11781165
    Abstract: Sedoheptulose, which is a saccharide falling within the categories of ketoses and heptuloses, is one of a small number of heptuloses occurring in nature. A method for producing sedoheptulose may use a bacterium, and/or may improve the productivity of sedoheptulose by the bacterium, and the bacterium. To solve this problem, provided are a method for producing sedoheptulose using a bacterium owing to the deletion or attenuation of a specific enzymatic function, a method for improving the productivity of sedoheptulose by the bacterium, and the bacterium.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: October 10, 2023
    Assignee: NAGASE & CO., LTD.
    Inventor: Shogo Yamamoto
  • Patent number: 11781125
    Abstract: Compositions and methods are provided for variant Cas systems and elements comprising such systems, including, but not limiting to, Cas endonuclease variants, guide polynucleotide/Cas endonuclease complexes comprising Cas endonuclease variants, as well as guide polynucleotides and guide RNA elements that can interact with Cas endonuclease variants. Compositions and methods are provided for genome modification of a target sequence in the genome of a cell. The methods and compositions employ a guide polynucleotide/Cas endonuclease system comprising a Cas9 endonuclease variant to provide an effective system for modifying or altering target sequences within the genome of a cell or organism.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: October 10, 2023
    Assignee: DANISCO US INC.
    Inventors: Ryan L. Frisch, Hongxian He
  • Patent number: 11773382
    Abstract: The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3?-phosphoadenosine 5?-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 3, 2023
    Assignee: OPTIMVIA, LLC
    Inventors: Tarsis Gesteira Ferreira, Daniel H. Lajiness
  • Patent number: 11767518
    Abstract: The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3?-phosphoadenosine 5?-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: September 26, 2023
    Assignee: OPTIMVIA, LLC
    Inventors: Tarsis Gesteira Ferreira, Daniel H. Lajiness
  • Patent number: 11767342
    Abstract: Herein is reported a method for the enzymatic production of an antibody with a modified glycosylation in the Fc-region comprising the steps of incubating the antibody light chain affinity ligand-bound monoclonal antibody with a glycosylation in the Fc-region with a first enzyme for a time sufficient and under conditions suitable to modify the glycosylation of the Fc-region, recovering the antibody from the antibody light chain affinity ligand, incubating the recovered antibody in solution with a second enzyme for a time sufficient and under conditions suitable to modify the glycosylation of the Fc-region to a defined form, separating the antibody with the modified glycosylation in the Fc-region from the second enzyme in a cation exchange chromatography, and thereby producing the antibody with a modified glycosylation in the Fc-region.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 26, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Dams, Roberto Falkenstein, Sebastian Malik, Ingrid Grunert, Marco Thomann, Matthias Freiherr Von Roman, Heiko Walch
  • Patent number: 11753615
    Abstract: The present disclosure belongs to the field of bioengineering, and relates to breeding of industrial microorganisms, in particular to a genetically engineered strain of Saccharomyces cerevisiae, method for constructing the same, and its use for brewing, the genetically engineered strain of Saccharomyces cerevisiae heterogeneously overexpresses an acetaldehyde dehydrogenase gene ALD6, an acetyl-CoA synthase gene ACS1 and an alcohol acyltransferase gene AeAT9. The Saccharomyces cerevisiae strain with high yield of ethyl acetate and low yield of higher alcohols provided by the present disclosure not only maintains excellent ethanol fermentation characteristics, but also reducing the production of higher alcohols which adversely affect the comfort after drinking, which is of great significance for a well-maintained and strengthened flavor characteristics of Chinese Baijiu, an improved and stabilized quality thereof, and even a reform in the fermentation process thereof.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: September 12, 2023
    Assignee: Tianjin University of Science and Technology
    Inventors: Yefu Chen, Wenqi Shi, Guo Zhang, Ruirui Li, Yanfang Chen, Huan Wang, Chunhong Sun, Dongguang Xiao, Xiaole Wu, Xuewu Guo
  • Patent number: 11753646
    Abstract: Provided are a tagatose-bisphosphate aldolase variant having tagatose conversion activity, and a method of preparing tagatose using the same.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 12, 2023
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Young Mi Lee, Eul-Soo Park, Il Hyang Park, Sun Mi Shin, Sung Jae Yang, Ran Young Yoon, Eun Jung Choi, Seong Bo Kim, Seung Won Park
  • Patent number: 11746351
    Abstract: A genetically engineered microorganism for the production of a cannabinoid biosynthetic pathway product is described. The genetically engineered microorganism comprises at least one nucleic acid molecule encoding at least one cannabinoid biosynthetic pathway enzyme. The disclosure also relates to methods for producing a cannabinoid biosynthetic pathway product using a genetically engineered microorganism.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: September 5, 2023
    Assignee: Algae-C Inc.
    Inventors: William Mather Almon Carscallen, Isabel Desgagné-Penix, Jean-Francois Lemay
  • Patent number: 11746130
    Abstract: The present disclosure relates to a novel protein variant having an activity of exporting 5?-inosine monophosphate, a microorganism comprising the protein variant, and a method for preparing 5?-inosine monophosphate using the microorganism.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: September 5, 2023
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jin Ah Rho, Byoung Hoon Yoon, So-jung Park, Min Ji Baek, Ji Hye Lee